naltrexone

Suppliers

Names

[ Name ]:
naltrexone

[Synonym ]:
Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-
Trexonil
NeMexin
(1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-on
Depotrex
ReVia
en1939
Naltrel
en1639
Naltrexone
Vivitrol
(5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one
Antaxone
trexan
(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-one
(1S,5R,13R,17S)-4-(cyclopropylméthyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadéca-7(18),8,10-trién-14-one
celupan
En 1639A
Um-792
(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
Nalorex
Depade

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
558.1±50.0 °C at 760 mmHg

[ Melting Point ]:
168-170ºC

[ Molecular Formula ]:
C₂₀H₂₃NO₄

[ Molecular Weight ]:
341.40

[ Flash Point ]:
291.4±30.1 °C

[ Exact Mass ]:
341.162720

[ PSA ]:
70.00000

[ LogP ]:
1.80

[ Vapour Pressure ]:
0.0±1.6 mmHg at 25°C

[ Index of Refraction ]:
1.709

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QD2155000

CHEMICAL NAME :: Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy -

CAS REGISTRY NUMBER :: 16590-41-3

LAST UPDATED :: 199806

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C20-H23-N-O4

MOLECULAR WEIGHT :: 341.44

WISWESSER LINE NOTATION :: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JQ P1- AL3TJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 551 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1100 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - delayed effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 21 mg/kg

SEX/DURATION :: female 10-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: Sex chromosome loss and nondisjunction

TYPE OF TEST :: Sex chromosome loss and nondisjunction

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Human Lymphocyte

DOSE/DURATION :: 1 gm/L

REFERENCE :: ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG. Volume(issue)/page/year: 1,180,1979

Safety Information

[ Symbol ]:

GHS02, GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H225-H301 + H311 + H331-H370

[ Precautionary Statements ]:
P210-P260-P280-P301 + P310-P311

[ Hazard Codes ]:
F,T

[ Risk Phrases ]:
11-23/24/25-39/23/24/25

[ Safety Phrases ]:
16-36/37-45

[ RIDADR ]:
UN1230 - class 3 - PG 2 - Methanol, solution

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

3,6,17-tris(cyclopropylcarboxy)oxymorphone
Novobiocin
(Bromomethyl)cyclopropane
Naltrexone Hydrochloride
Nor Oxymorphone
Cyclopropanecarboxyldehyde
Cyclopropyl carbinol
Naltrexone 3-Methyl Ether
(Chloromethyl)cyclopropane

DownStream

Articles

Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

J. Pharmacol. Exp. Ther. 350(1) , 69-78, (2014)

The opioid and cannabinoid systems play a crucial role in multiple physiological processes in the central nervous system and in the periphery. Selective opioid as well as cannabinoid (CB) receptor ago...

Desensitization of functional µ-opioid receptors increases agonist off-rate.

Mol. Pharmacol. 86(1) , 52-61, (2014)

Desensitization of µ-opioid receptors (MORs) develops over 5-15 minutes after the application of some, but not all, opioid agonists and lasts for tens of minutes after agonist removal. The decrease in...

Treatment of alcohol dependence: recent progress and reduction of consumption.

Minerva Med. 105(6) , 447-66, (2014)

Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra...